Elite Pharmaceuticals, Inc. Deferred Federal Income Tax Expense (Benefit)
Elite Pharmaceuticals, Inc. (ELTP) reported Deferred Federal Income Tax Expense (Benefit) of $10.34 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-06-29
- Elite Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2026 was $10.34M, a 166.99% increase from fiscal 2025.
- Elite Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $3.87M.
- Elite Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$19.71M.
- Elite Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$2.17M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2026-03-31 | $10.34M 10-K · filed 2026-06-29 | |
| 2025-03-31 | $3.87M 10-K · filed 2026-06-29 | |
| 2024-03-31 | -$19.71M 10-K · filed 2025-06-30 | |
| 2022-03-31 | -$2.17M 10-K · filed 2023-06-29 | $2.17M 10-K · filed 2022-06-29 |
| 2018-03-31 | $0.00 10-K · filed 2018-06-14 | |
| 2017-03-31 | $0.00 10-K · filed 2018-06-14 | |
| 2016-03-31 | $0.00 10-K · filed 2018-06-14 | |
| 2015-03-31 | $0.00 10-K · filed 2017-06-14 | |
| 2014-03-31 | $0.00 10-K · filed 2016-06-15 | |
| 2013-03-31 | $0.00 10-K · filed 2014-06-30 | |
| 2012-03-31 | $0.00 10-K · filed 2013-06-21 |